Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein- deficient mice

Journal of the National Cancer Institute

Volumn 88, Issue 14, 1996, Pages 994-999

  Van Asperen, Judith ^a   Schinkel, Alfred H ^a   Beijnen, Jos H ^b   Nooijen, Willem J ^a   Borst, Piet ^a   Van Tellingen, Olaf ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LD 50; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, MULTIPLE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; MICE; P-GLYCOPROTEIN; TISSUE DISTRIBUTION; VINBLASTINE;

EID: 0029952418     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.14.994     Document Type: Article

References (35)

1. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cells. Science 1983;221: 1285-8.
2. Riordan JR, Ling V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979;254:12701-5.
3. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pasian I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
4. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86:695-8.
5. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988;48:1926-9.
6. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989;9:1346-50.
7. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci U S A 1988; 85:4350-4.
8. Teeter LD, Becker FF, Chisari FV, Li DJ, Kuo MT. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 1990;10:5728-35.
9. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
10. Gros P, Dhir R, Croop J, Talbot F. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci U S A 1991;88:7289-93.
11. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
12. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8: 689-704.
13. Sikic BI. Modulation of multidrug resistance: at the threshold [editorial] [see comment citation in Medline]. J Clin Oncol 1993;11:1629-35.
14. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993;53:747-54.
15. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma [see comment citation in Medline]. J Natl Cancer Inst 1991;83:111-16.
16. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON [see comment citation in Medline]. Lancet 1992;340:255-9.
17. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnen M, Roe DJ, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78:44-50.
18. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia [see comment citation in Medline]. J Clin Oncol 1993;11:1652-60.
19. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9:17-24.
20. Cairo MS, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 1989;49:1063-6.
21. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993;72:3553-63.
22. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial [see comment citation in Medline]. J Clin Oncol 1994;12:1771-7.
23. Linn SC, van Kalken CK, van Tellingen O, van der Valk P, van Groeningen CJ, Kuiper CM, et al. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 1994;12:812-9.
24. Bates SE, Meadows B, Goldspiel BR, Denicoff A, Le TB, Tucker E, et al. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemother Pharmacol 1995;35: 457-63.
25. Verweij J, Herweijer H, Oosterom R, van der Burg ME, Planting AS, Seynaeve C, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 1991;64:361-4.
26. Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parrillo JE, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-7.
27. Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shepard K, et al. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol 1988;6:880-8.
28. Millward MJ, Lien EA, Robinson A, Cantwell BM. High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology 1994;51:79-83.
29. Leveque D, Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 1995;15:331-6.
30. Colombo T, Zucchetti M, D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 1994;269:22-7.
31. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994; 12:835-42.
32. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42.
33. van Tellingen O, Beijnen JH, Nooijen WJ, Bult A, Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography. Cancer Chemother Pharmacol 1993;32:286-92.
34. van Tellingen O, Beijnen JH, Nooijen WJ, Bult A. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography. Cancer Res 1993;53:2061-5.
35. Owellen RJ, Hartke CA, Hains FO, Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977;37(8 Pt 1):2597-602.